Eldecalcitol 艾地骨化醇; ED-71; 2-(3-hydroxypropoxy-1,25-dihydroxyvitamin D3)|cas:104121-92-8|西域试剂

Eldecalcitol 艾地骨化醇; ED-71; 2-(3-hydroxypropoxy-1,25-dihydroxyvitamin D3),99.85%

产品编号：Bellancom-A0020| CAS NO：104121-92-8| 分子式：C₃₀H₅₀O₅| 分子量：490.72

Eldecalcitol（ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3）是1,25-二羟基维生素D3的类似物。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-A0020	￥1600.00	杭州北京（现货）
Bellancom-A0020	￥6950.00	杭州北京（现货）
Bellancom-A0020	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Eldecalcitol 艾地骨化醇; ED-71; 2-(3-hydroxypropoxy-1,25-dihydroxyvitamin D3)

产品介绍

Eldecalcitol (ED-71) 是一种具有口服活性维生素 D3 类似物，可抑制骨吸收并增加骨密度。Eldecalcitol 具有抗肿瘤作用，抑制细胞增殖、迁移，并通过抑制 GPx-1 来诱导细胞凋亡 (apoptosis)。

生物活性

Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1^[4].

体外研究

Eldecalcitol (0-50 nM; 24 h) displays no cytotoxicity, and (0.5-50 nM; 24 h) reduces cell death induced by LPS (5 μg/mL).
Eldecalcitol (5 nM; 24 h) inhibits the LPS-induced pyroptosis by activating Nrf2 and its effector molecule HO-1.
Eldecalcitol (0.5-50 nM; 24 h) exhibits anti-pyroptotic ability, and decreases NLRP3, caspase-1, and IL-1β expression dose-dependently.
Eldecalcitol (0.04-40 nM; 0-48 h) inhibits the proliferation and migration of SCC-15 and CAL-27 cells.
Eldecalcitol (0.4 nM; 48 h) arrests cell cycle at G0/G1 phase and induces apoptosis by suppressing the expression of GPx-1 (glutathione peroxidase) in OSCC cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Human gingival fibroblasts (HGFs)
Concentration:	0, 0.5, 5, and 50 nM
Incubation Time:	24 hours
Result:	Decreased TLR4, NLRP3, caspase-1 p20, ASC, and GSDMD-N level in a dose-dependent manner compared with the group treated with LPS. Reduced the release of IL-1β and IL-18 induced by LPS to normal levels.

Cell Proliferation Assay

Cell Line:	SCC-15 and CAL-27 cells
Concentration:	0, 0.04, 0.4, 4, and 40 nM
Incubation Time:	6, 8, 12, 24, 48 hours
Result:	Inhibited the cell viability of the OSCC cells to reach 50% at 24 h with 0.4 nM.

Cell Proliferation Assay

Cell Line:	OSCC cells
Concentration:	0.4 nM
Incubation Time:	48 hours
Result:	Increased the proportion of cells at the late phases of apoptosis from 7.1% to 16.1%. Upregulated Bax and caspase-3, downregulated Bcl-2. Significantly triggered apoptosis in SCC- 15 and CAL- 27 cells.

体内研究
(In Vivo)

Eldecalcitol (0.5 μg/kg; p.o.; twice a week for 4 weeks) displays anti-cancer effect by GPx-1 (glutathione peroxidase) inhibition.
Eldecalcitol (10, 30, or 90 ng/kg; p.o.; 5-times per week for 12 weeks), as a more potent vitamin D3 analog, stimulates focal bone formation (minimodeling) and suppresses bone resorption more strongly than does calcitriol^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Xenograft tumor model in mice (male athymic nude BALB/c mice)
Dosage:	0.5 μg/kg
Administration:	Oral gavage; twice a week for 4 weeks
Result:	Reduced the growth rate of tumors, and downregulated the expression levels of PCNA and MMP- 2 and upregulated the expression of Bax in the tumors. Resulted in decrease of proliferation, the inhibition of migration, and the promotion of apoptosis.

Animal Model:	Ovariectomized (OVX) rat model^[4]
Dosage:	10, 30, or 90 ng/kg
Administration:	Oral gavage; 5-times per week for 12 weeks
Result:	Increased the lumbar and femoral BMD in a dose dependent manner. Stimulated focal bone formation that started without prior bone resorption, a process known as bone minimodeling.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Xenograft tumor model in mice (male athymic nude BALB/c mice)
Dosage:	0.5 μg/kg
Administration:	Oral gavage; twice a week for 4 weeks
Result:	Reduced the growth rate of tumors, and downregulated the expression levels of PCNA and MMP- 2 and upregulated the expression of Bax in the tumors. Resulted in decrease of proliferation, the inhibition of migration, and the promotion of apoptosis.

Animal Model:	Ovariectomized (OVX) rat model^[4]
Dosage:	10, 30, or 90 ng/kg
Administration:	Oral gavage; 5-times per week for 12 weeks
Result:	Increased the lumbar and femoral BMD in a dose dependent manner. Stimulated focal bone formation that started without prior bone resorption, a process known as bone minimodeling.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Xenograft tumor model in mice (male athymic nude BALB/c mice)
Dosage:	0.5 μg/kg
Administration:	Oral gavage; twice a week for 4 weeks
Result:	Reduced the growth rate of tumors, and downregulated the expression levels of PCNA and MMP- 2 and upregulated the expression of Bax in the tumors. Resulted in decrease of proliferation, the inhibition of migration, and the promotion of apoptosis.

Animal Model:	Ovariectomized (OVX) rat model^[4]
Dosage:	10, 30, or 90 ng/kg
Administration:	Oral gavage; 5-times per week for 12 weeks
Result:	Increased the lumbar and femoral BMD in a dose dependent manner. Stimulated focal bone formation that started without prior bone resorption, a process known as bone minimodeling.

性状

Solid

溶解性数据

In Vitro:

Methanol : 8.33 mg/mL (16.98 mM; Need ultrasonic)

DMSO : 3.33 mg/mL (6.79 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0378 mL	10.1891 mL	20.3782 mL
5 mM	0.4076 mL	2.0378 mL	4.0756 mL
10 mM	0.2038 mL	1.0189 mL	2.0378 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

参考文献

. Matsumoto T.Osteoporosis Treatment by a New Active Vitamin D3 Compound, Eldecalcitol, in Japan.Curr Osteoporos Rep. 2012 Aug 24. [Content Brief]

. Huang C, et al. Eldecalcitol Inhibits LPS-Induced NLRP3 Inflammasome-Dependent Pyroptosis in Human Gingival Fibroblasts by Activating the Nrf2/HO-1 Signaling Pathway. Drug Des Devel Ther. 2020 Nov 13;14:4901-4913. [Content Brief]

. Lu Y, et al. Eldecalcitol inhibits the progression of oral cancer by suppressing the expression of GPx-1. Oral Dis. 2021 Aug 24. [Content Brief]

[4]. Saito H, et al. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone. J Steroid Biochem Mol Biol. 2013 Jul;136:178-82. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

1. 物质的识别

产品名：	Eldecalcitol
CAS号：	104121-92-8
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Eldecalcitol
别名：	ED-71; Edirol; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
分子式：	C30H50O5
分子量：	490.72

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	4°C, protect from light, sealed

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。